Roche to Acquire GenMark Diagnostics for $1.8B


  • Roche to acquire all outstanding shares of GenMark’s for $24.05/ share in cash, making a total deal value of $1.8B with a premium of ~43% to GenMark’s closing price on Feb 10, 2021. The acquisition is expected to be completed in Q2’21
  • The acquisition will boost Roche’s molecular diagnostics portfolio and will expand the global reach of GenMark’s products
  • GenMark deliver molecular diagnostic tests designed to detect multiple pathogens from a single patient sample and its respiratory pathogen panels complement Roche’s COVID-19 diagnostics solutions

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Forbes

The post Roche to Acquire GenMark Diagnostics for $1.8B first appeared on PharmaShots.